amunix logo.jpg
Amunix Pharmaceuticals Announces the Appointment of Dr. Bryan Irving as Chief Scientific Officer
June 26, 2019 07:05 ET | Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...
amunix logo.jpg
Amunix Expands Executive Team with Appointment of Dr. Mika Derynck as CMO, Dr. Darcy Mootz as CBO, and Yvonne Li as SVP of Finance
May 14, 2019 08:05 ET | Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on the discovery and development of novel protein therapeutics,...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio Announces US FDA Approval of the Investigational New Drug Application for TNB-383B and the Initiation of Phase I Clinical Studies in Multiple Myeloma Patients
April 29, 2019 08:00 ET | TeneoBio, Inc
NEWARK, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that their investigational new drug application (IND) for TNB-383B, a bispecific...
Merus Announces Financial Results for the Full Year 2018 and Provides Business Update
April 03, 2019 16:00 ET | Merus N.V.
UTRECHT, The Netherlands, April 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies
January 08, 2018 08:00 ET | TeneoBio, Inc
MENLO PARK, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Teneobio, Inc., a next generation multi-specific antibody therapeutics company announced today the initiation of a research collaboration and...
Teneo_logo_FINAL_whitebkgnd.png
TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology
December 11, 2017 08:00 ET | TeneoBio, Inc
MENLO PARK, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- TeneoBio, Inc. yesterday presented preclinical data on its lead therapeutic candidate, TNB-383B, a multivalent anti-BCMAxCD3 at the American...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio and Poseida Announce License Agreement for the Use of UniDab™ in CAR T-Cell Therapy
May 22, 2017 08:00 ET | TeneoBio, Inc
MENLO PARK, Calif. and SAN DIEGO, May 22, 2017 (GLOBE NEWSWIRE) -- Teneobio, Inc. and Poseida Therapeutics, Inc. today announced that they have entered a commercial license agreement for the use of...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio’s Next Generation T Cell Redirection Antibody Platform for Cancer Biotherapeutics Offers Prospects of Reducing Cytokine Release
May 01, 2017 08:00 ET | TeneoBio, Inc
MENLO PARK, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Teneobio, Inc, a next-generation antibody therapeutics company, announced today at the Protein Engineering Summit (PEGS) in Boston the discovery...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer
February 13, 2017 08:30 ET | OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Feb. 13, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and...
OncoMed Pharmaceuticals, Inc. Logo
OncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients
January 04, 2017 08:30 ET | OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and...